Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $69.96 million. The enterprise value is -$19.20 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 89.70 million shares outstanding. The number of shares has increased by 389.92% in one year.
| Current Share Class | 89.70M |
| Shares Outstanding | 89.70M |
| Shares Change (YoY) | +389.92% |
| Shares Change (QoQ) | +16.18% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 27.77% |
| Float | 40.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 48.80, with a Debt / Equity ratio of 0.00.
| Current Ratio | 48.80 |
| Quick Ratio | 47.02 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.59% and return on invested capital (ROIC) is -39.69%.
| Return on Equity (ROE) | -55.59% |
| Return on Assets (ROA) | -38.01% |
| Return on Invested Capital (ROIC) | -39.69% |
| Return on Capital Employed (ROCE) | -34.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.30M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.29% in the last 52 weeks. The beta is 2.12, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.12 |
| 52-Week Price Change | -58.29% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 1.47 |
| Relative Strength Index (RSI) | 44.98 |
| Average Volume (20 Days) | 95,929 |
Short Selling Information
The latest short interest is 2.20 million, so 2.45% of the outstanding shares have been sold short.
| Short Interest | 2.20M |
| Short Previous Month | 2.35M |
| Short % of Shares Out | 2.45% |
| Short % of Float | 5.42% |
| Short Ratio (days to cover) | 9.88 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -31.63M |
| Pretax Income | -18.57M |
| Net Income | -27.63M |
| EBITDA | -31.62M |
| EBIT | -31.63M |
| Earnings Per Share (EPS) | -$0.36 |
Full Income StatementBalance Sheet
The company has $89.35 million in cash and $193,706 in debt, giving a net cash position of $89.16 million or $0.99 per share.
| Cash & Cash Equivalents | 89.35M |
| Total Debt | 193,706 |
| Net Cash | 89.16M |
| Net Cash Per Share | $0.99 |
| Equity (Book Value) | 90.98M |
| Book Value Per Share | 1.01 |
| Working Capital | 90.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.22 million and capital expenditures -$41,264, giving a free cash flow of -$15.27 million.
| Operating Cash Flow | -15.22M |
| Capital Expenditures | -41,264 |
| Free Cash Flow | -15.27M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |